39th week of 2021 patent applcation highlights part 11 |
Patent application number | Title | Published |
20210299218 | NEUROPROTECTIVE COMPOSITIONS AND USE THEREOF - The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided. | 2021-09-30 |
20210299219 | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF CORNEAL HAZE AND SCARRING - This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent. | 2021-09-30 |
20210299220 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION - In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof. | 2021-09-30 |
20210299221 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF - The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12. In some embodiments, the open reading frame is sequence-optimized. In particular embodiments, the disclosure provides sequence-optimized polynucleotides comprising nucleotides encoding the polypeptide sequence of human IL12, or sequences having high sequence identity with those sequence optimized polynucleotides. | 2021-09-30 |
20210299222 | THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS - The disclosure relates to a liquid pharmaceutical composition of aldesleukin/SDS aggregates and its use in the treatment of auto-immune disease, inflammatory disorders, gene therapies and cancer. A method for preparing said composition is also described. | 2021-09-30 |
20210299223 | USE OF INTERLEUKIN-7 AND CHIMERIC ANTIGEN RECEPTOR (CAR)-BEARING IMMUNE EFFECTOR CELLS FOR TREATING TUMOR - Disclosed herein are therapeutic uses for treating cancer in a subject in need thereof, comprising administering to the subject a population of chimeric antigen receptor (CAR)-bearing immune effector cells and an IL-7 protein (e.g., modified IL-7 protein). | 2021-09-30 |
20210299224 | Methods and Compositions for Treating Autoimmune and Inflammatory Conditions - Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (APC)-targeted antibody operatively linked to IL-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders. | 2021-09-30 |
20210299225 | COMPOSITION FOR TREATING OR SENSITIZING INTERFERON BETA RESISTANT CANCER DISEASE COMPRISING CFLIP SIRNA - The present invention relates to a composition for treating or sensitizing interferon beta resistant cancer disease comprising cFLIP siRNA, and, more specifically, to a pharmaceutical composition for treating interferon beta resistant cancer disease, comprising, as an active ingredient: (a) an siRNA complementarily binding to mRNA of a cFLIP gene; and (b) a human interferon beta variant which comprises glycine-asparagine-isoleucine-treonine-valine sequence (GNITV) at C-terminus in a human natural interferon beta amino acid sequence shown in SEQ ID NO: 1, or has replaced the 27 | 2021-09-30 |
20210299226 | METHOD OF TREATING AND PREVENTING CORONAVIRUSES WITH LOW DOSAGE INTERFERON BETA-1A AS A TH17 INHIBITOR - This invention relates to methods for usages, dosing and delivery of interferon beta-1a for use in children, adults and other mammals for the prevention and treatment of coronaviruses including COVID-19 with the direct delivery of interferon beta-1a to the Th17 receptors in the mucosal surfaces of the intestinal and pulmonary tract for the prevention of Th17 downstream cytokines. This inventor uses interferon beta-1a as a Th17-inhibitor to the mucosal surfaces of the lung and intestine in low dosages of 10,000 IU and below. The invention also provides for interferon beta-la used in combination with antiviral pharmaceuticals to also benefit the prevention and treatment of coronaviruses including COVID-19. | 2021-09-30 |
20210299227 | Growth-Promoting Supplement for Livestock - A growth-promoting supplement for livestock is a meal additive for hair growth, tail growth, and nail growth. The growth-promoting supplement also promotes hair, tail, and nail strength. The growth-promoting supplement includes a quantity of gelatin, a quantity of Biotin, a quantity of Lysine, a quantity of Vitamin E, and a quantity of Methionine. The composition is heterogeneously mixed into a powdered mixture that may be mixed into a meal for livestock. The composition further includes a quantity of alfalfa powder. Alternatively, the composition further includes a quantity of current-health-based additives. The current-health-based additives includes a quantity of Vitamin C, a quantity of Zinc, a quantity of Omega-3 fatty acids, and combinations thereof. Both the quantity of alfalfa powder and the quantity of current-health-based additives are heterogeneously mixed into the powdered mixture according the specific dietary needs and health condition of the livestock. | 2021-09-30 |
20210299228 | Drug Carrier, Brain-targeting Nanodrug Based on CRISPR Gene Editing Technology and Preparation Method and Use thereof - The present disclosure provides a drug carrier, a brain-targeting nanodrug based on CRISPR gene editing technology and a preparation method and use thereof. The nanodrug contains nanoparticles prepared by coupling Cas9/sgRNA and drug carriers. The drug carrier includes a polymer mPEG-P (GPMA, FPMA) and a polymer Ang-PEG-PGPMA, wherein a structural formula of the mPEG-P (GPMA, FPMA) is: | 2021-09-30 |
20210299229 | USE OF LOW pH ACTIVE ALPHA-1,4;/1,6-GLYCOSIDE HYDROLASES (GLCH) AS A FEED ADDITIVE FOR RUMINANTS TO ENHANCE STARCH DIGESTION - Disclosed are uses at least one alpha-1,4/1,6-glycoside hydrolase (GLCH) as a feed additive for a ruminant wherein said hydrolase: (a) has at least 20% activity at pH less than or equal to 3 in the presence of pepsin as compared to activity of the hydrolase at pH 6 in the presence of pepsin, (b) said hydrolase is active in at least two of three digestive chambers of a ruminant comprising a rumen, an abomasum and a small intestine and (c) the hydrolase works with pancreatic amylase to increase glucose yield. | 2021-09-30 |
20210299230 | MEDICINE FOR COVID-19 AND TREATMENT - The invention concerns a medicine and a prophylactic medicine for COVID-19 disease. The inventive medicine targets the endosomic, non-endosomic and/or intracellular viral pathways and inhibits them. The best mode of the invention is considered to be the medicine that blocks all three viral pathways. In the best mode the individual dose of a constituent component of the medicine is arranged to a dosage size sufficient to inhibit its designated SARS-CoV-2 viral pathway. This allows the dose of a particular pharmacological agent to be smaller than in a drug with just one kind of pharmacological agent. The best mode of the invention shuts the two cell membrane viral pathways and the one intracellular viral pathway with the minimum efficient dose, thereby preventing drug overdose, and enabling prophylactic or preventive use. | 2021-09-30 |
20210299231 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS USING BOTULINUM TOXIN - A method for treating Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, in a patient in need thereof comprises administering botulinum toxin to the patient. The botulinum toxin may be administered by subcutaneous or intradermal injection. The injection may be administered to and/or around the vicinity of a trigeminal nerve, a cervical nerve, a thoracic nerve, a lumbar nerve, and/or a sacral nerve of the patient. The administration of the botulinum toxin prevents an overproduction of glutamate, Substance P, and CGRP in a sensory system and thereby inhibits a migration of the glutamate, Substance P, and CGRP to the motor system, which otherwise would cause neuroexcitatory toxicity that results in the death of motor neurons. | 2021-09-30 |
20210299232 | INJECTION PARADIGM FOR ADMINISTRATION OF BOTULINUM TOXINS - Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine. | 2021-09-30 |
20210299233 | METHOD FOR TREATING CANCER - Described herein are methods and compositions for treating cancer. Aspects of the invention relate to administering to a subject having cancer an asparaginase and an agent that inhibits GSK3f. Another aspect of the invention relates to administering an asparaginase to a subject having cancer that comprises an inactivating mutation in GSK3f. | 2021-09-30 |
20210299234 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Embodiments are directed to: (i) neutrophil secreted factors that have the capacity to kill a broad range of cancer cells without affecting the viability of non-cancer cells. Two neutrophil killing factors have been identified by the inventors: (1) eosinophil cationic protein (ECP) and (2) neutrophil elastase (ELANE); or (ii) therapeutic compositions that include CD95 degrading polypeptide components and methods of treating cancer with the same. | 2021-09-30 |
20210299235 | METHODS OF TREATING POLYCYSTIC KIDNEY DISEASE - Methods of preventing and treating PKD and its complications using antibody activators that bind to the (Na | 2021-09-30 |
20210299236 | Methods and Compositions for Enhancing Vaccine Immune Responses - Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus Ankara (MVA) comprising a nucleic acid sequence encoding a CD40 ligand (CD4OL) and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increases T-cell immune responses specific for the heterologous disease-associated antigen when administered to a human host, and related methods and uses. | 2021-09-30 |
20210299237 | TRITERPENE SAPONIN SYNTHESIS, INTERMEDIATES AND ADJUVANT COMBINATIONS - The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases. | 2021-09-30 |
20210299238 | COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE BROAD-SPECTRUM HUMAN PAPILLOMAVIRUS FORMULATIONS - Embodiments of the present invention provide for novel compositions and methods for making and using a thermally stable broad spectrum human papilloma virus (HPV) vaccine or immunogenic formulation. Certain embodiments concern lyophilizing HPV formulations in the presence or absence of adjuvants. Other embodiments concern lyophilizing HPV capsomere vaccines and other immunogenic agents to increase stability or reduce degradation of HPV peptides to prolong storage, delivery and use. In yet other embodiments, a single immunogenic formulation can include a thermally stable composition of a broad-spectrum HPV immunogenic composition against multiple HPV types. In some embodiments, a stabilizing formulation can include RG1 HPV16VLP antigens in a hypertonic mixture of a disaccharide and a volatile buffer. | 2021-09-30 |
20210299239 | NOVEL TH1-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS, AND USE OF SAME - The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. | 2021-09-30 |
20210299240 | COMPOSITE POLYPEPTIDE MONOMER, AGGREGATE OF SAID COMPOSITE POLYPEPTIDE MONOMER HAVING CELL PENETRATION FUNCTION, AND NOROVIRUS COMPONENT VACCINE FOR SUBCUTANEOUS, INTRADERMAL, PERCUTANEOUS, OR INTRAMUSCULAR ADMINISTRATION AND HAVING SAID AGGREGATE AS EFFECTIVE COMPONENT THEREOF - The present invention addresses the issue of providing a norovirus component vaccine for subcutaneous, intradermal, percutaneous, or intramuscular administration which vaccine can readily immunize the target cells, an associated product of a molecular needle serving as an active ingredient of the vaccine, and a production method for the associated product. The invention provides a norovirus component vaccine containing, as an active ingredient, an associated product including a hexamer formed through bonding of two molecules of a trimer of a molecular needle represented by the following formula (1). W-L | 2021-09-30 |
20210299241 | REVERSE PEPTIDE VACCINE - The invention relates to vaccine compositions comprising peptides encoded by an open reading frame (ORF) encoded by at least part of the genome of a ssRNA virus in the opposite sense to positive sense RNA capable of translation, and the use of such compositions for the treatment and prevention of viral infection. | 2021-09-30 |
20210299242 | NIPAH VIRUS IMMUNOGENS AND THEIR USE - Embodiments of immunogens comprising a recombinant Nipah virus (NiV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant NiV F ectodomain trimer and one or more G ectodomains, a multimer of NiV G ectodomains, and protein nanoparticles comprising the recombinant NiV F ectodomain trimer or an NiV G ectodomain. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits NiV infection in a subject. | 2021-09-30 |
20210299243 | IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY - Provided herein are methods for inducing an immune response against an antigen in a subject. In some embodiments, the methods comprise administering a therapeutically effective amount of a vaccine and an interleukin 10 (IL-10) inhibitor to the subject. In some embodiments, the vaccine is an IL-10-deficient vaccine. | 2021-09-30 |
20210299244 | IMMUNOGENIC COMPOSITION FORMING A VACCINE, AND A METHOD FOR ITS MANUFACTURE - An immunogenic composition forming a vaccine includes a nanoparticle delivery system comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a nucleic acid encoding a protein from a coronavirus. | 2021-09-30 |
20210299245 | ATTENUATED POXVIRUS VECTOR BASED VACCINE FOR PROTECTION AGAINST COVID-19 - The present invention relates to a composition for raising an immune response in an animal which prevents or decreases the risk of a coronavirus infection and decreases severity of disease. In particular, the invention relates to vaccines and/or immunogenic compositions for raising an immune response in an animal which prevents or decreases the risk of the SARS-CoV-2 disease named COVID-19 by the World Health Organization. The composition comprises an attenuated poxvirus, and especially a vaccinia virus, wherein the attenuated poxvirus genome comprises a coronavirus SARS-CoV-2 nucleic acid sequence encoding the spike protein polypeptide and or the membrane protein polypeptide and or nucleocapsid protein polypeptide and or envelope protein polypeptide or an immunogenic or functional part of any of these. | 2021-09-30 |
20210299246 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT OF VIRAL OR VIRALLY-INDUCED INFECTIONS AND CONDITIONS, AND ANTI-VIRAL COMPOSITIONS AND THEIR PRODUCTION - Methods and compositions for treating a viral infection, where the cells from the host to be treated are extracted from the host and modified with viral DNA, and then replaced back to the host to generate an immune response. The composition may be produced using fat cells that are mechanically or chemically transformed to a nanofat, and co-incubation of the nanofat with the adenovirus. The double-stranded DNA of the adenovirus codes for a specific antibody to be produced, and the transfer of genetic material from the virus to the nanofat stem cells takes place outside of the host where the host immune system cannot destroy it. The co-incubated cells are then administered to the host by introduction into the nasal passages or directive cavity, or through injection or other vehicle. The compositions provide an effective rapid response to an invasive pathogen, such as an adenovirus or bacteria, through passive immunity. | 2021-09-30 |
20210299247 | STABLE FORMULATIONS OF CYTOMEGALOVIRUS - The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol. | 2021-09-30 |
20210299248 | HUMAN HERPESVIRUS IMMUNOTHERAPY - An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens. | 2021-09-30 |
20210299249 | RECOMBINANT MULTIVALENT INFLUENZA VIRUSES - The invention provides a composition useful to prepare influenza vaccine viruses, e.g., in the absence of helper virus, which includes internal viral segments from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and encodes a heterologous antigen. | 2021-09-30 |
20210299250 | STIMULATOR OF INTERFERON GENES (STING) LIGANDS AND USES THEREOF - Provided herein are Stimulator of Interferon Genes (STING) ligand for use in enhancing immune response and/or as adjuvants in vaccines. In some embodiments, STING ligand is used alone or in combination with Alum in an adjuventation system for early life immunization. | 2021-09-30 |
20210299251 | IMMUNOGENIC COMPOSITION FORMING A VACCINE, AND A METHOD FOR ITS MANUFACTURE - An immunogenic composition forming a vaccine includes a nanoparticle adjuvant comprising at least a nanoparticle, wherein the at least a nanoparticle comprises a lipid layer exterior including a plurality of lipids, cholesterol, and a primary alkyl amine including a positively charged amino group head and at least a carbon tail and an antigen incorporated in the at least a nanoparticle, wherein the antigen comprises a spike protein from a coronavirus. | 2021-09-30 |
20210299252 | BACTERICIDAL/PERMEABILITY INCREASING PROTEIN FOR USE IN A METHOD OF IMMUNIZATION, PREFERABLY AS AN ADJUVANT IN A METHOD OF VACCINATION - The present invention relates to bactericidal/permeability increasing protein (BPI) for use in a method of immunization of a patient, preferably as an adjuvant in a method of vaccination. The present invention also relates to a preparation comprising BPI for use in a method of immunization of a patient, and optionally an immunomodulatory agent. The present invention further relates to a process of producing a preparation including BPI for use in a method of immunization of a patient. | 2021-09-30 |
20210299253 | NOVEL AUTOTAC CHIMERIC COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING DISEASES THROUGH TARGETED PROTEIN DEGRADATION COMPRISING THE SAME - The present invention relates to a novel AUTOTAC chimeric compound in which a new p62 ligand and a target-binding ligand are connected by a linker, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for the prevention or treatment of diseases by degrading the target protein including the same as an active ingredient. They can target specific proteins to adjust their concentrations, and can also deliver drugs and other small molecule compounds to lysosomes. The AUTOTAC chimeric compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various diseases by selectively eliminating specific proteins. | 2021-09-30 |
20210299254 | COMPOSITIONS AND METHODS FOR TREATING CROHN'S DISEASE AND RELATED CONDITIONS AND INFECTIONS - In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNFα composition, or a composition capable of down-modulating TNFα activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti | 2021-09-30 |
20210299255 | COMPOSITIONS OF FCRN ANTIBODIES AND METHODS OF USE THEREOF - Stable pharmaceutical compositions containing an anti-FcRn antibody are described and characterized. | 2021-09-30 |
20210299256 | ULTRASOUND MEDIATED DELIVERY OF DRUGS - The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions. | 2021-09-30 |
20210299257 | Methods, Systems and Apparatus for Reducing Pathogen Loads in Circulating Body Fluids - A nanocomposition for use in treating a pathogen condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a pathogen targeting peptide. Administering a product comprising IR700 to a patient, whereby the IR700 is delivered to pathogen tissue, and found in only pathogen tissue; and administering light to activate the IR700, thereby producing an ROS. | 2021-09-30 |
20210299258 | PHOTODYNAMIC COMPOSITIONS AND METHODS OF USE - The present invention is directed to compositions and methods targeting cells in a subject harboring conditions or at risk for conditions that would benefit from gas-based diagnoses and therapies. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent, including gaseous substances, delivered in combination with the fluorochemical composition. The present invention also relates to the use of fluorochemical compositions in conjunction with oxygen and photo sensitizers to enhance photodynamic diagnosis and photodynamic therapy. | 2021-09-30 |
20210299259 | STARCH-BASED RELEASE MODIFYING EXCIPIENTS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM - There is provide an extended release dosage form comprising a release modifying excipient comprising high amylose starch, cross-linked hydroxypropylated amylopectin, and a pre-gelatinized common starch; wherein the release modifying excipient is substantially free of crosslinks between amylose and amylopectin and substantially free of crosslinks between amylose and amylose. It has been found that the extended release properties of conventional cross-linked high amylose starches (e.g., Contramid®) can be reproduced by intimately mixing i) cross-linked chemically modified amylopectin; ii) a high amylose, non-chemically modified starch and; iii) a pre-gelatinized common starch. Producing a release modifying excipient in this way means that no chemical cross linking between (a) amylose and amylopectin or (b) amylose and amylose has occurred—properties heretofore considered vital for Contramid® function. The release modifying excipient blends overcome problems associated with use of Contramid, and provide a flexible platform for formulation of active pharmaceutical ingredients for controlled release applications. | 2021-09-30 |
20210299260 | THERAPEUTIC CONJUGATES - Provided herein is a class of anti-cancer conjugates designed to cross the blood-brain barrier (BBB) and thereby deliver a methylation agent into cancerous tumor cells, wherein the conjugate comprises a BBB-shuttle moiety that allows the conjugate to cross the BBB, and at least two methylation moieties of the methyltriazene type attached thereto for effecting DNA methylation in the cancerous cells. Also provided are uses of the conjugates in the treatment of brain cancer. | 2021-09-30 |
20210299261 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY - Provided herein are compositions, methods of making the same, and methods for targeted delivery of therapeutic agents for modifying expression and function of target genes, e.g. proteins involved in lipid and cholesterol metabolism such as PCSK9. Further provided herein are compositions and methods of treating conditions related to coronary disease. | 2021-09-30 |
20210299262 | COMPOSITION AND METHOD FOR DUAL TARGETING IN TREATMENT OF NEUROENDOCRINE TUMORS - Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone αvβ3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors. | 2021-09-30 |
20210299263 | CELL-PENETRATING PEPTIDES - The present invention relates to peptides, in particular cell-penetrating peptides, and to conjugates of such cell-penetrating peptides with a therapeutic molecule. The present invention further relates to use of such peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders and in particular muscular dystrophies such as Duchenne muscular dystrophy. | 2021-09-30 |
20210299264 | CELL-PENETRATING PEPTIDES - the present invention relates to peptides, in particular cell-penetrating peptides, having a first hydrophobic domain positioned at the C-terminus of the peptide and a second hydrophobic domain positioned at the N-terminus of the peptide, and to conjugates of such cell-penetrating peptides with a therapeutic molecule. The present invention further relates to use of such peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders and in particular muscular dystrophies such as Duchenne muscular dystrophy. | 2021-09-30 |
20210299265 | EFFICIENT PROCESS FOR PREPARING CELL-BINDING AGENT-CYTOTOXIC AGENT CONJUGATES - The present invention provides a novel method for preparing a cell-binding agent cytotoxic agent conjugate. The method comprises the step of reacting a cell-binding agent with a cytotoxic agent or a cytotoxic agent-linker compound having a reactive group capable of forming a covalent bond with the cell-binding agent at a pH between 4 to 9 in the presence of a buffer solution with high ionic strength, wherein the cell-binding agent comprises a lysine ε-NH | 2021-09-30 |
20210299266 | COMPOSITIONS AND METHODS OF TREATING MUSCLE DYSTROPHY - Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1). | 2021-09-30 |
20210299267 | COMPLEX CAPABLE OF INHIBITING GENETIC FUNCTION IN EXOSOME, AND CANCER PROLIFERATION AND/OR METASTASIS SUPPRESSOR - The present invention provides a conjugate comprising an antibody or antibody fragment targeting an exosome surface antigen, and an inhibitor of a gene or an expression product thereof, wherein the antibody or antibody fragment and the inhibitor of a gene or an expression product thereof are covalently bonded either directly or via a linker, or are non-covalently bonded. | 2021-09-30 |
20210299268 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES - The present disclosure relates to antibody-drug conjugates comprising ALK5 inhibitors and their uses. | 2021-09-30 |
20210299269 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE - Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative. | 2021-09-30 |
20210299270 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES - The present invention relates to anti-matriptase antibodies and immunoconjugates of anti-matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising an anti-matriptase monoclonal antibody and anticancer agents such as auristatin, including monomethyl auristatin E (MMAE) and monomethyl auristatin F (MMAF) are introduced, which have potent antitumor activity in vivo. Moreover, importantly; there was no weight loss or other evidence of toxicity in the animals, indicating that no significant free drug was released into the circulation from the conjugate. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of an anti-matriptase antibody or immunoconjugates of an anti-matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers. | 2021-09-30 |
20210299271 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS - The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention. | 2021-09-30 |
20210299272 | METHODS AND COMPOSITIONS FOR DRUG DELIVERY - Compositions comprising a dual-targeted nanoparticle having a first targeting moiety and a second targeting moiety, wherein said first targeting moiety is a red blood cell (RBC)-targeting moiety are provided. In certain embodiment, the nanoparticles are bound to RBCs ex vivo. Also provided are methods of delivering selected drugs to target organs using these compositions for treatment of disease or for diagnostic imaging. | 2021-09-30 |
20210299273 | NANOPARTICLE COMPOSITIONS - Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (I): A-L-B. | 2021-09-30 |
20210299274 | ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR - Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided. | 2021-09-30 |
20210299275 | GENE THERAPY FOR THE TREATMENT OF GALACTOSEMIA - Provided herein are recombinant AAV vectors encoding a GALT protein. Also provided in this disclosure are compositions and methods for the treatment of galactosemia. | 2021-09-30 |
20210299276 | METHODS OF EXPLOITING ONCOGENIC DRIVERS ALONG THE HUMAN CYCLIN G1 PATHWAY FOR CANCER GENE THERAPY - The present disclosure teaches methods of treating a patient having an advanced metastatic cancer by administering a plurality of infusions of a first therapeutic agent comprising a tumor-targeted gene vector that encodes a cytocidal inhibitor of the CCNG1 gene product and a second therapeutic agent that affects the activity of at least one additional molecular target along the CCNG1 pathway. The additional molecular target may be Mdm2, PP2A, p53, Rb, c-Myc, or a cyclin-dependent kinase. The present disclosure also provides methods of treatment by administering a plurality of infusions of a first therapeutic agent comprising a tumor-targeted gene vector that encodes a cytocidal inhibitor of the CCNG1 gene product and a second therapeutic agent such as an immune-modulatory monoclonal antibody, a cytotoxic chemotherapeutic agent, an anti-angiogenesis agent, a selective tyrosine kinase inhibitor, or a monoclonal antibody directed against specific features of cells from the metastatic cancer. Further, the disclosure provides methods of treating a palpable tumor, methods for evaluating the role of oncogenic drivers along the Cyclin G1 pathway in a tumor, and methods of treatment that use such evaluations/analyses to guide the management of the disease. | 2021-09-30 |
20210299277 | Gene Therapy for NMNAT1-Associated Retinal Degeneration - Methods and compositions for gene therapy of retinal degeneration related to mutations in nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1). | 2021-09-30 |
20210299278 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2021-09-30 |
20210299279 | METHODS AND COMPOSITIONS FOR TREATING A PREMATURE STOP CODON-MEDIATED DISORDER - Modified tRNAs can be used to express in a mammalian cell a functional gene product encoded by a gene containing a premature stop codon and/or to treat a disease mediated by a premature stop codon. | 2021-09-30 |
20210299280 | COMPOSITIONS AND METHODS FOR TRANSIENT GENE THERAPY WITH ENHANCED STABILITY - The present invention provides circularized RNA and methods of making and using same. | 2021-09-30 |
20210299281 | MULTIPLE BIOMARKERS IMAGING FOR HIGH SPECIFICITY - A method of imaging cancer stem cells comprises disposing a population of first ultrasound-switchable fluorophorms having a first switching threshold in the biological environment, the first ultrasound-switchable fluorophores being functionalized for attachment to a first biomarker expressed by the CSCs; disposing a population of second ultrasound-switchable fluorophorms having a second switching threshold in the biological environment, the second ultrasound-switchable fluorophores being functionalized for attachment to a second biomarker expressed by the CSCs; exposing the biological environment to an ultrasound beam to form an activation region; disposing one or more of the first and/or second ultrasound-switchable fluorophores in the activation region to switch the first and/or second fluorophores from an off state to an on state; exciting the first and second ultrasound-switchable fluorophores in the activation region with a beam of electromagnetic radiation; and detecting light emitted by the first and second ultrasound-switchable fluorophores. | 2021-09-30 |
20210299282 | Device for Collecting and Culturing Fish Embryos and Method for Evaluating Combined Toxicity of Thiamethoxam and Tetraconazole - A device and a method are disclosed for collecting and culturing fish embryos and evaluating combined toxicity of thiamethoxam and tetraconazole. An embryo collection component and an embryo culture component are provided on a base plate. The embryo collection component includes a collection tray detachably connected to a bottom of a culture tube. The embryo culture component includes a cavity plate with a stopper inside and a top plate provided with a culture well. A bottom of the culture well is provided with a leakage hole; and after the top plate is installed into the cavity plate, the stopper occludes the leakage hole. The new device is used to carry out the combined toxicity effect test of thiamethoxam and tetraconazole on zebrafish embryos, which can be used to avoid development of pesticide mixtures that have a good preventive effect but pose increased toxicity risk to the ecological environment. | 2021-09-30 |
20210299283 | PEPTIDES AND ANTIBODIES FOR DETECTING CHANGES IN ALZHEIMER'S DISEASE BRAIN AND METHODS OF USE THEREOF - The present invention is based on the seminal discovery of a panel of targeting peptides and antibodies that can recognize AD brains at different stages of the disease, starting from early to advanced stage. The peptide probes described here are unique in the field and can be expected to advance understanding on early neurodegenerative changes associated with AD and improve the therapeutic outcomes by early detection and intervention in AD. Further, the invention provides antibodies that can be used to treat AD. | 2021-09-30 |
20210299284 | METHOD AND MATERIAL TO ACQUIRE MAGNETIC RESONANCE IMAGING DATA - Provided are MR images of a subject gastrointestinal tract structure in which the lumen of the structure is usefully darkened on both T1-weighted and T2-weighted images when the structure is imaged following administration to the subject of an enteric contrast agent formulation with particles containing encapsulated gas or partial vacuum. The present invention provides an encapsulated gas or partial vacuum particle contrast medium of use in acquiring such MR images. In an exemplary embodiment, the invention provides an enteric contrast medium formulation. An exemplary formulation comprises, (a) an enteric contrast medium comprising a encapsulated gas or partial vacuum particle suspended in water. | 2021-09-30 |
20210299285 | COMPOUNDS USEFUL FOR IN VIVO IMAGING OF PROTEIN OXIDATION AND/OR CANCER TREATMENT - Provided herein are compounds of Formula I, Formula II Formula III which are useful in labeling tissues in a subject (e.g., PET imaging of a subject), for treatment of cancer, and/or for preparing a medicament. Also provided are compounds containing a group that is reactive with sulfenylated proteins for treatment of cancer and/or for preparing a medicament. Methods of synthesis of the compounds and precursor compounds are also provided. | 2021-09-30 |
20210299286 | TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD - Disclosed herein are tetrazines substituted with groups that result in a high click conjugation yield in vivo and high click release yields. In one aspect, the invention relates to kits having the tetrazines and a dienophile, preferably a trans-cyclooctene. In another aspect, the kits of the invention are for use as a medicament. | 2021-09-30 |
20210299287 | PLANT TREATMENT EQUIPMENT - A system for treating plant material uses a vessel capable of being brought to a vacuum and/or pressurized and maintained at a relatively low temperature. Plant material is placed within the vessel and the vessel draws a vacuum or is pressurized. A control system may monitor and control the creation of a vacuum, flow rate of a gas from a gas tank into the vessel, the temperature in the vessel, the flow rate of gas out of the vessel, and the pressure of the vessel. | 2021-09-30 |
20210299288 | APPARATUSES AND METHODS TO ATTENUATE VIRUSES - A virus attenuator includes: a housing defining an interior and having at least one intake port fluidly coupled to the interior and a gas ejection nozzle fluidly coupled to the interior, the gas ejection nozzle being configured to couple to a mask; and at least one heater disposed in the interior between the at least one intake port and the gas ejection nozzle such that at least some gas brought into the interior through the at least one gas intake port contacts the at least one heater. The at least one heater is configured to heat contacting gas to a virus attenuating temperature before the contacting gas exits the interior through the gas ejection nozzle. | 2021-09-30 |
20210299289 | METHODS AND APPARATUS FOR VOLUMETRIC INACTIVATION OF VIRUSES BY ACOUSTIC RESONANCE STIMULATION USING NON-IONIZING GIGAHERTZ ELECTROMAGNETIC RADIATION - According to some aspects, there is provided a method of selectively inactivating viruses through acoustic resonance by non-ionizing gigahertz electromagnetic radiation. In some implementations, there is provided an apparatus comprising a power processing unit; a microwave source; an antenna; a control unit; wherein the spatial and temporal characteristics of the electromagnetic field are optimized to maximize viral inactivation at the target location while minimizing overall radiation exposure. Methods of delivering high peak energy into the virus structure with minimal total average power are also provided. | 2021-09-30 |
20210299290 | DOWNLIGHT APPARATUS FOR UV-DEACTIVATION OF PATHOGENS - An apparatus for performing ultraviolet-deactivation of pathogens is disclosed. The disclosed apparatus includes a housing, a base member, one or more visible light assemblies, and one or more ultraviolet radiation assemblies. The housing is configured to define a downlight aperture region irradiated by the apparatus. The apparatus may additionally include sensors to detect whether a living organism occupies the downlight aperture region. The input from the sensors may be used to control the one or more ultraviolet radiation assemblies. | 2021-09-30 |
20210299291 | SYSTEMS AND METHODS FOR UV-C INACTIVATED VIRUS VACCINES AND UV-C SANITIZATION - An UV-C device may include several UV-C light sources (e.g., UV-C LEDs) and such UV-C LEDs may have UV-C reflecting structures arranged to direct UV-C in a particular direction and at a particular size and shape. Doing so may, for example, increase the UV-C in a particular direction or working area. A UV-C generating device may be utilized in an air duct to sterilize air through that air duct. A UV-C generating device may, for example, be utilized to increase the amount of UV-C that enters a UV-C fiber optic tube. A UV-C generating device may be utilized, for example, to inactivate one or more virus (e.g., one or more different viruses and/or one or more claves of the same virus) and a UV-C inactivated virus may be utilized as a vaccination. A facility may be provided that received strains from the same clave and/or different claves and that UV sterilizes (e.g., UV-C sterilizes) the strains and combines the strains into a combinational UV-C vaccination of multiple UV-C inactivated strains. | 2021-09-30 |
20210299292 | Method to Kill Respiratory Viruses and Microbes by Water Mist Charge - The invention relates to an electrostatic aerosol disinfection and sterilization method. The method includes the following steps: atomizing liquid water without any medicine to obtain atomized particles of liquid water; and carrying the atomized particles on Static electricity of a first polarity; transporting atomized particles with static electricity to a predetermined surface of an object to be disinfected, the objects to be disinfected have static electricity of a first polarity; when the atomized particles reach the object to be disinfected When the predetermined surface is changed, the electrostatic polarity of the object to be disinfected is changed, so that the object to be disinfected has static electricity of a second polarity, wherein the second polarity is opposite to the polarity of the first polarity. The present invention is capable of treating and slowing down various respiratory diseases caused by viruses, including new pneumonia that threatens people all over the world, greatly improves the effect of disinfection and sterilization, is not only safe and reliable, but also has simple operation and low cost. | 2021-09-30 |
20210299293 | SOLID WASTE TREATMENT CENTER FOR MITIGATION OF INFECTIOUS PATHOGEN SPREAD - Mixed solid waste is transported from a waste collection vehicle to a first room of a waste treatment facility. The first room defines an enclosed isolation zone that is configured to receive the mixed solid waste from the waste collection vehicle. The mixed solid waste is treated in at least one process vessel in the first room to destroy a majority of pathogens in the mixed solid waste to yield a sanitized waste. The sanitized waste is transported to a second room of the facility. The second room defines a clean zone that is separated from the first room by a barrier. | 2021-09-30 |
20210299294 | SURFACE COATING CONFIGURED TO ENHANCE UV STERILIZATION AND METHOD OF MANUFACTURING THE SAME - A surface coating configured to locally enhance ultraviolet light density of ultraviolet light incident on the surface coating. The surface coating includes a dielectric layer, a conductive layer on the dielectric layer, a series of nano-openings in the dielectric layer and the conductive layer, a series of nano-antennae in the series of nano-openings, and a dielectric gap between the series of nano-antennas and the conductive layer. The conductive layer and the nano-antennae both include a UV plasmonic material. | 2021-09-30 |
20210299295 | METHOD OF AUTONOMOUS MOBILE DISINFECTION - Implementations of the disclosed subject matter provide a method of receiving, at an actuated mobile device, at least one dosage level for a predetermined area, where the at least one dosage level is based on a first dosage of ultraviolet (UV) light to be output from at least one light source for at least a portion of the predetermined area. The method may include moving the actuated mobile device in a path within the predetermined area and outputting the UV light from the at least one light source onto one or more first surfaces based on the received at least one dosage level. The method may include moving the actuated mobile device within the path, and outputting the UV light onto one or more second surfaces based on the received at least one dosage level. | 2021-09-30 |
20210299296 | DISINFECTION AND STERILIZATION APPARATUS AND METHOD, AND DISINFECTION AND STERILIZATION CONTROL APPARATUS - A disinfection and sterilization control apparatus includes a disinfection and sterilization control component configured to obtain usage data of a space; and a disinfection and sterilization component electrically coupled to the disinfection and sterilization control component and configured to disinfect and sterilize the space under the control. The disinfection and sterilization control component controls the disinfection and sterilization component to perform disinfection and sterilization operation when the usage data meets a condition of triggering a disinfection and sterilization operation. When the usage data of the space meets the condition, the disinfection and sterilization apparatus is controlled to automatically disinfect and sterilize the space, achieving smart and effective disinfection and sterilization on an interior space, for example of an elevator car, thereby avoiding cross contamination, ensuring service safety of the elevator and protecting users' health. | 2021-09-30 |
20210299297 | Forward Emitting Ultraviolet Helmet - A headlamp for killing microorganisms on a surface is disclosed. The headlamp includes a head strap for donning the headlamp onto a head, a light source emitting ultraviolet light that sanitizes surfaces in which the ultraviolet light contacts, and an adjustment mechanism that adjusts the light source with respect to the head strap in a direction the user is looking such that the light emitted from the light source contacts said surface. A proximity sensor powers on the light source when the user is within a predetermined distance away from the surface. A timer powers off the light source when the light source has contacted the surface for predetermined amount of time. An indicator provides a que that the surface is safe to touch. A motion detector powers the light source on when motion is detected proximate thereto and powers off the light source absent motion proximate thereto. | 2021-09-30 |
20210299298 | PORTABLE STERILIZATION DEVICE - In one aspect, a portable sterilization device configured to be carried by an individual is disclosed, which comprises a wearable element configured for removable and replaceable coupling to a body part of the individual, an ultraviolet light emitting diode (UV LED) coupled to said element and positioned so as to emit radiation into an external environment, and a portable power supply for supplying electrical power to said UV LED. | 2021-09-30 |
20210299299 | DEVICE FOR ERADICATING BACTERIA AND VIRUSES - A device for eradicating bacteria and viruses using ultraviolet C (UV-C) light. The device includes a two-dimensional array of ultraviolet (UV) light sources and a two-dimensional array of sensors interspersed between the UV light sources. A structural skeleton may surround the UV light sources and the sensors. The structural skeleton may be configured to support the weight of a user wearing shoes such that the user can stand on the device above the planes created by the UV light array and the sensor array. Critically, the device includes a controller that determines the location of an object on a top surface of the device based on the output of the sensors and controls the UV light sources to emit UV-C light towards the bottom surface of the object. | 2021-09-30 |
20210299300 | SYSTEMS AND METHODS FOR INCREASING WORK AREA AND PERFORMANCE OF UV-C GENERATORS - A UV-C generator is provided where multiple UV-C LEDs are provided around a work area (e.g., a tube) in order to sterilize contaminants in that work area (e.g., virus and/or bacteria) to provide a sterilization device for substances in, or flowing through, the work area. The tube may gates to change the speed and/or direction of a flowing working substance and may have a spiraling channel in the tube such that the length of travel in the spiraling channel is longer than the tube. Such UV-C generator devices may be utilized, for example, to sanitize air flowing through devices such as a ventilator or face mask. | 2021-09-30 |
20210299301 | SYSTEMS AND METHODS FOR INCREASING WORK AREA AND PERFORMANCE OF UV-C GENERATORS - A UV-C generator is provided where multiple UV-C LEDs are provided around a work area (e.g., a surface) in order to sterilize contaminants in that work area (e.g., virus and/or bacteria). The sterilization device can be utilized, for example, in a wand, broom, set distance surface sterilizer, hand sanitizer, foot sanitizer, conveyer sanitizer, or any other sanitizer. Mating structures may be included to mate multiple devices to extend work area that may be impacted. The devices may be portable and may include one or more rechargeable batteries. | 2021-09-30 |
20210299302 | SYSTEMS AND METHODS FOR HANDS-FREE OBJECT STERILIZATION - A hands-free object sanitization system is provided where multiple UV-C LEDs are provided around a work area (e.g., a surface) in order to sterilize contaminants located on objects placed in that work area (e.g., virus and/or bacteria). Objects may travel through the work area without direct human intervention so that a hands-free sanitization system is provided. For example, objects may be dropped through a working area so that gravity provides a transport force through that working area. | 2021-09-30 |
20210299303 | UV-C VIRUS INACTIVATION DEVICES AND SUPRESSING SOUND AND OPERATING THE SAME - An UV-C device may include several UV-C light sources (e.g., UV-C LEDs) and such UV-C LEDs may have UV-C reflecting structures arranged to direct UV-C in a particular direction and at a particular size and shape. Doing so may, for example, increase the UV-C in a particular direction or working area. A UV-C generating device may be utilized in an air stream, such as an air duct, to sterilize air from that air stream. Sound suppression compartments may be placed around a UV-C generating device inlet and/or a device outlet to reduce sound from the UV-C generating device. Human perceivable (e.g., audible, tactile, and/or visual) notifications may be utilized to provide notification of different modes of operation and/or different efficacy levels (e.g., percent ranges of inactivation of a particular or multiple particular viruses, bacteria, spores, etc. | 2021-09-30 |
20210299304 | STERILIZATION SYSTEMS USING UV LIGHT - Systems and methods for sterilizing items, such as respirators, masks, and other personal protection equipment, using UV-C light are disclosed herein. In some embodiments, counter-top systems for providing 360-degree germicidal irradiation of respirators and other items are disclosed herein. In some embodiments, the systems include one or more UV-C lamps positioned inside of a rotatable structure that supports items for sterilization, and one or more UV-C lamps positioned outside of the rotatable support structure. | 2021-09-30 |
20210299305 | Apparatus for cleaning an object - An apparatus that disinfects hand-held devices has a sealed interior disinfecting chamber designed to fit handheld devices of various sizes and surround them with disinfectant in a gaseous state. The base of the interior chamber has vertically disposed pegs of equal height that serve as an aerated pedestal on which to place a handheld device to allow gas to circulate beneath and around it. A fan evaporates disinfectant from the sealed chamber prior to unsealing the chamber. | 2021-09-30 |
20210299306 | STERILIZING METHOD AND STERILIZER - A sterilizing method for sterilizing a sterilization object housed in a chamber | 2021-09-30 |
20210299307 | STERILIZATION METHODS FOR STERILIZING A SURGICAL INSTRUMENT HAVING AN ANTIMICROBIAL COATING - A sterilization method is provided for sterilizing a surgical instrument having an antimicrobial coating formed from applying a solution including a silane quaternary ammonium ion or salt thereof, the method comprising sterilizing the surgical instrument using a low temperature sterilization technique. The low temperature sterilization technique may include low temperature autoclave, exposure to ultraviolet light, exposure to gamma ray radiation, chemical sterilization, or any combination thereof. The chemical sterilization may include sterilization with ethylene oxide. | 2021-09-30 |
20210299308 | Disinfection System - The present invention relates to a disinfection system comprising a plurality of replaceable containers, to contain a solution comprising a disinfecting agent, conduits leading from the containers to a manifold, misting apparatus to generate a mist containing the disinfecting agent and to release the mist via exit conduits, through at least one exit vent, wherein the manifold comprises a plenum which receives a volume of air for controlling balance of air pressure as the air is released through the at least one exit vent. The present invention also relates to a method of controlling use of a disinfection system. | 2021-09-30 |
20210299309 | TENT WITH ANTIMICROBIAL TREATMENT APPLIED THERETO AND METHOD OF IMPARTING ANTIMICROBIAL PROPERTIES TO THE TENT - A tent comprising an exposed surface and an antimicrobial substance applied to the exposed surface. The tent can further include an interior. The exposed surface can be disposed within the interior. The tent can include a fabric. The fabric can provide the exposed surface. The tent can be a medical center. The antimicrobial substance can be a silane quaternary ammonium ion or salt thereof. The silane quaternary ammonium ion can be one or more of: 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium ion, 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride, 3-(trihydroxysilyl)propyldimethyloctadecyl ammonium ion, and 3-(trihydroxysilyl)propyldimethyloctadecyl ammonium chloride. | 2021-09-30 |
20210299310 | COPPER BEARING SUBSTRATE FOR ODOUR CONTROL - A substrate having discrete copper laminae for positioning proximate an odour causing area of a user's body. The lamina are spaced apart to provide channels between adjacent laminae and the substrate. The high density of the laminae and channels cooperate to control odour. Several embodiments are disclosed for use in a variety of clothing and footwear articles. | 2021-09-30 |
20210299311 | Multifunction Disinfection Drone Apparatus and Method - An autonomous drone operated remotely via wireless networks is instructed by its owner flying about in an unoccupied room to activate a system of selectable air and surface disinfection modules. An air purifier captures particles in ambient air and switches on an oscillating motion tubular shaped cage mounted with a plurality of Ultraviolet C spectrum, long range zoom and focusable lens LED projectors to disinfect virus and bacteria. A fan assisted forced air Ozone generator module speeds up disinfecting inconspicuous spots to destroy hidden viruses. Disinfection is completed after the half-life time of dispensed Ozone and an oxygen recovery module rapidly converts residual ozone still in air back to normal oxygen molecules enabling a shortened waiting time for occupants to return to the treated room. A negative ions module subsequently switches on to refresh the air. | 2021-09-30 |
20210299312 | STERILIZING METHOD AND STERILIZER - A sterilizing method for sterilizing a sterilization object housed in a chamber | 2021-09-30 |
20210299313 | COMBUSTION DEVICE ADAPTED TO THE DIFFUSION OF FRAGRANCE - A combustion device adapted to the diffusion of fragrance has a main body which has an internal space divided into a heating zone and a fuel zone and defines a ventilation hole. The heating zone is adjacent to the top of the main body. The fuel zone is adjacent to the bottom of the main body. The fuel zone receives a wick. The ventilation hole extends vertically to the heating zone. The combustion device also includes a fragrance diffuser diffusing fragrance disposed in the heating zone. The fragrance diffuser includes an insulator and a fragrance holder housed by the insulator. The insulator defines a hollow above the wick and a groove. The fragrance holder is disposed in the groove. | 2021-09-30 |
20210299314 | CHEMICAL SOLUTION SPRAYING DEVICE - A chemical solution spraying device supplies a chemical solution to a target space. An offensive odor is generated in the target space. The chemical solution spraying device includes a sprayer and a control unit. The sprayer sprays the chemical solution. The control unit controls at least one of a start timing of a spray operation of the sprayer and a spray amount at a start of the spray operation of the sprayer based on a condition of the target space. | 2021-09-30 |
20210299315 | Ultraviolet-Free Antiviral Air-Filtering Lighting Device - A lighting device that comprises a housing, a first visible light source, a second visible light source, an air filter, an airway, and an air circulation mechanism for each airway. The first visible light source contributes to the light output of the device, whereas the second visible light source is responsible for germicidal irradiation by activating a visible-light activatable photocatalytic coating on the air filter. The airway has an air inlet and an air outlet. The air circulation mechanism sucks an ambient air through the air inlet, forces the air through the air filter, and releases the air through the air outlet. The air filter traps airborne particles. The second visible light source is disposed adjacent to the air filter and activates a photocatalyst material in the antiviral photocatalytic coating. Airborne microbials trapped by the air filter are decomposed by the activated photocatalyst material in the antiviral photocatalytic coating. | 2021-09-30 |
20210299316 | UV-C AMPLIFIERS AND CONTROL OF THE SAME - A UV-C Amplifier is provided where multiple UV-C LEDs are provided around a work area (e.g., a hollow cylinder) in order to sterilize contaminants in that work area (e.g., virus and/or bacteria) to provide a sterilization device for substances in, or flowing through, the work area. The sterilization device have, for example, mating structures so that the device may be mated with other devices such as, for example, a ventilator or face mask. The sterilization device may be portable and may include one or more rechargeable batteries so that the device can sterilize material flowing into, through, and/or out of one or more devices such as a ventilator or face mask. | 2021-09-30 |
20210299317 | SYSTEMS AND METHODS FOR EFFICIENT AIR STERILIZATION WITHOUT CIRCULATION UNSANITIZED AIR - An air sanitization device is provided where a UV-C generator applied UV-C to infected air for sterilization and then the sterilized air is used to cool heat sinks attached to the UV-C. One or more fans can be utilized to push and/or pull air through the device. For example, the fans may create airflow in the device above, for example 200 liters per minute or above 400 liters per minute. Accordingly, a closed air system with a fan may push air through a UV-C generation device to sanitize air and the sanitized air may be pushed over a heat sink attached to the UV-C generation device and then pushed out of the closed air system into the environment. Thus, sanitized air may be circulated by the fan while being air cooled in a manner that does not circulate contaminated air. | 2021-09-30 |